In this edition of our Guidelines+ Monographs Series, we will be taking a look at Bristol-Myers Squibb’s medication apixaban, brand name Eliquis. Initially approved in 2012, Eliquis is a factor Xa inhibitor, an anticoagulant used to prevent stroke and systemic embolism in nonvalvular atrial fibrillation, and to treat deep vein thrombosis (DVT) and pulmonary embolism […]
A list of all the FDA approved medications in June 2024.
Breyanzi (Bristol Myers Squibb)Expanded Indication Retevmo (Eli Lilly) Expanded Indication Onyda XR (Tris Pharma) Bkemv (Amgen)Biosimilar to Soliris Opuviz (Biogen) Biosimilar to Eylea Yesafili (Biocon Biologics) Biosimilar to Eylea Imdelltra (Amgen) Clinolipid (Baxter) Expanded Indication ColoSense (Geneoscopy) New Formulation Myhibbin (Azurity Pharmaceuticals) New Formulation Cyltezo (Boehringer Ingelheim) New Formulation Sign up for alerts and stay informed on […]
On April 22, 2024, the US Food and Drug Administration (FDA) approved ImmunityBio’s first-in-class interleukin-15 superagonist (IL-15) nogapendekin alfa inbakicept-pmln (Anktiva), plus bacillus Calmette-Guérin (BCG), for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. Designated an FDA Breakthrough Therapy, the novel immunotherapy […]